VYGR Company Profile and Key Details

Q: Who are the executives of VYGR?

Mr. Todd Carter Ph.D.Chief Science OfficerDr. Mark A. Kay M.D., Ph.D.FounderMr. Peter P. Pfreundschuh CPAChief Financial OfficerDr. Phillip D. ZamoreFounderMr. Robert W. HessleinSenior Vice President & Gen. CounselMr. G. Andre TurenneAdvisorDr. Alfred W. Sandrock Jr., M.D., Ph.D.Pres, Chief Executive Officer & DirectorDr. Phillip D. Zamore Ph.D.Founder & Member of Scientific Advisory BoardDr. Krystof Bankiewicz M.D., Ph.D.FounderMs. Robin SwartzChief Operating OfficerMs. Michelle Quinn SmithChief HR OfficerMr. Robert W. Hesslein Esq., J.D.Senior Vice President & Gen. CounselMs. Jacquelyn Fahey Sandell Esq., J.D.Chief Legal Officer

NASDAQ : VYGR

Voyager Therapeutics

$3.88

0.12+3.19%

At Close 4:00 PM

66.71

BESG ScoreESG Rating

Profile Key Stats Analyst Ratings Ownership Ratios Financials Dividend & splits Sentiment Forecast

Price Chart

Stock Price Today

Voyager Therapeutics, Inc. (VYGR) stock surged +3.19%, trading at $3.88 on NASDAQ, up from the previous close of $3.76. The stock opened at $3.82, fluctuating between $3.75 and $3.88 in the recent session.

Stock Snapshot

3.76

Prev. Close

234M

Market Cap

3.75

Day Low

-1.9

P/E Ratio

-2.04

EPS (TTM)

1.65

Cash Flow per Share

3.82

Open

60.31M

Number of Shares

3.88

Day High

82.64%

Free Float in %

5.37

Book Value

361.76K

Volume

Relevant Articles

SEC Fillings

Current Report (8-k)

Filing Date	Accepted Date

Annual Report (10-k)

Filing Date	Accepted Date

Stock Price History Chart

Date	Open	High	Low	Close	Volume
May 04, 2026	3.75	3.88	3.75	3.88	361.77K
Apr 30, 2026	3.65	3.81	3.64	3.73	403.98K
Apr 29, 2026	3.75	3.76	3.63	3.64	343.78K
Apr 28, 2026	3.75	3.83	3.73	3.77	249.67K
Apr 27, 2026	3.78	3.87	3.74	3.76	368.64K
Apr 23, 2026	4.14	4.14	4.01	4.04	323.04K
Apr 22, 2026	4.01	4.21	4.01	4.14	429.26K
Apr 21, 2026	4.25	4.27	4.12	4.12	375.8K
Apr 20, 2026	4.16	4.34	4.11	4.23	395.24K
Apr 17, 2026	4.05	4.18	4.00	4.13	860.98K
Apr 16, 2026	3.98	4.01	3.89	3.96	341.74K
Apr 14, 2026	3.85	4.05	3.85	3.94	559.32K
Apr 13, 2026	3.74	3.94	3.74	3.84	534.51K
Apr 10, 2026	3.97	3.97	3.67	3.74	787.11K
Apr 09, 2026	3.89	4.01	3.86	3.96	646.19K
Apr 08, 2026	4.00	4.06	3.86	3.92	638.74K
Apr 07, 2026	3.95	3.98	3.76	3.96	576.48K
Apr 06, 2026	3.95	4.04	3.86	3.97	816.08K
Apr 02, 2026	3.91	3.96	3.80	3.96	462.51K
Apr 01, 2026	3.89	4.09	3.89	3.99	507.76K

Contact Details

Lexington, MA 02139

United States

https://www.voyagertherapeutics.com 857 259 5340

About Company

Voyager Therapeutics, Inc., a gene therapy company, focuses on the development of treatments and next-generation platform technologies. The company's lead clinical candidate is the VY-AADC, which is in open-label Phase 1 clinical trial for the treatment of Parkinson's disease. Its preclinical programs comprise VY-SOD102 for the treatment of amyotrophic lateral sclerosis; VY-HTT01 for Huntington's disease; VY-FXN01 for Friedreich's ataxia; and Tau program for the treatment of tauopathies, including Alzheimer's disease, progressive supranuclear palsy, and frontotemporal dementia, as well as for spinal muscular atrophy. The company has collaboration and license agreements with Neurocrine Biosciences, Inc., Pfizer Inc., and Novartis Pharma, A.G. for the research, development, and commercialization of adeno-associated virus gene therapy products. Voyager Therapeutics, Inc. was incorporated in 2013 and is headquartered in Cambridge, Massachusetts.

Stock Peers

ARGX

27.59+3.52%

argenx SE$811.09 REGN

7.79+1.11%

Regeneron Pharmaceuticals, Inc.$709.21 UTHR

10.82+1.90%

United Therapeutics Corporation$581.22 MDGL

4.94002+0.96%

Madrigal Pharmaceuticals, Inc.$518.66 VRTX

5.93+1.40%

Vertex Pharmaceuticals Incorporated$429.85 PRAX

13.41+4.14%

Praxis Precision Medicines, Inc.$337.61 KRTX

0.09+0.03%

Karuna Therapeutics, Inc.$329.83 ALNY

1.815+0.61%

Alnylam Pharmaceuticals, Inc.$297.93 KRYS

20.91+7.86%

Krystal Biotech, Inc.$286.95 SGEN

-0.16-0.07%

Seagen Inc.$228.74

Company Overview

Voyager Therapeutics, Inc. (NASDAQ:VYGR) closed at $3.88 USD, gaining $0.12 (3.19%) from the previous close of $3.76. The stock is currently mid-range between its 52-week high and low $2.65 and $5.55. With a market capitalization of about $234.00 million, Voyager Therapeutics, Inc. is classified as a micro-cap and shows market-like volatility (beta ~1.26). Key stats such as the average daily volume over the past year has been around 655.34 thousand shares, volume is running light vs its 52-week average. Headquartered in Lexington, MA, Voyager Therapeutics, Inc. operates in the Healthcare sector and the Biotechnology industry. Led by CEO Alfred W. Sandrock Jr., the company employs approximately 172 people and listed since November 11, 2015. Voyager Therapeutics, Inc., a gene therapy company, focuses on the development of treatments and next-generation platform technologies.

Technical Performance

Short-term trend indicators are mixed aligned (SMA20 14.39%, SMA50 8.6%, SMA200 10.23%). The stock’s 14-day RSI is 65.61 (firm momentum), while the ATR of 0.23 points to higher daily volatility. The stock remains hovering near 52-week lows, trading -23.78% below its high and over 59.92% above its low. Average 10-day trading volume of 345.56 thousand shares is below the 3-month average of 669.25 thousand, indicating normal recent market interest.

Valuation Metrics

Voyager Therapeutics, Inc. trades at a P/E ratio of -1.89, slightly below the S&P 500 average, with a price-to-sales ratio of 5.75 and a price-to-book ratio of 1.15 suggesting the stock is closer to book value. The P/FCF stands at -1.72, also below market averages.

Dividend & Fair Value

Voyager Therapeutics, Inc. last paid a dividend of 0 per share, Dividend and splits history remains an important factor for investors monitoring long-term returns. A discounted cash flow model estimates fair value at around -$3.44. This means the shares are trading below this model’s fair value.

Earnings & Analyst Outlook

Voyager Therapeutics, Inc. generated EPS of -$2.17 over the past year. Five-year average earnings growth is 1.48%. Wall Street analysts project EPS growth of -11.34% annually over the next five years. The latest quarter delivered EPS of -$0.46. The next quarter is forecast at -$0.51. Next year's EPS is expected at -$291.78. Analyst sentiment is bullish. Analyst rating data shows there are 1 Strong Buy ratings, 3 Buy ratings, 0 Hold ratings, 0 Sell rating and 0 Strong Sell ratings. Price targets range from $30.00 to $8.00. The high target offers 673.2% upside. The low target suggests 106.19% downside. The mean target is $22.00. This offers 467.01% upside. Voyager Therapeutics, Inc. earnings surprise history is a mixed track record. The quarter that ended March 09, 2026, missed forecasts by -14.81%. The prior quarter beat by -3.2%. Over the last six quarters, Apple has recorded several small beats. These include -64.44% in November 12, 2024.

Shareholding & Insider Activity

Voyager Therapeutics, Inc. has 55.47 million shares outstanding. The public float is 45.84 million shares, elevated short interest at 6.33% of float. This equals 2.94 million shares. The short ratio is 3.74 days. Institutional investors hold 70.73% of the float. Insiders own 15.35%. NEUROCRINE BIOSCIENCES INC holds 8.58 million shares, TEPPER ROBERT I has 5.43 million shares and Third Rock Ventures III, L.P. has 4.69 million shares. Over the past six months, insider transactions show net selling. They sold 80.21 thousand shares across 11 transactions.

Financial & Profitability Overview

Over the trailing twelve months, Voyager Therapeutics generated $250.01M in revenue, or $5.61 per share. Gross margin was 98.22%, operating margin 48.80%, and net profit margin 52.93%. Returns are exceptional, with ROA at 37.67% and ROE at 56.00%.
On valuation metrics, Voyager Therapeutics trades at a P/E of -1.89, P/S of 5.75 and P/B of 1.15. The current ratio is 7.64 and quick ratio is 7.64. Operationally, the company’s inventory turnover is 0.00 and cash conversion cycle is 15.92 days. Debt-to-equity is 0.19, supported by a cash flow-to-debt ratio of -3.63.

Quarterly Financial Highlights

For the quarter ended Dec 31, 2023, Voyager Therapeutics posted revenue of $250.01M, down slightly from $40.91M in the prior quarter. Gross profit was $245.57M (margin 98.22%). Operating income was $122.01M (margin 48.8%). Net income was$132.33M (EPS $3.08).
The company ended the quarter with $230.88M in cash and short-term investments, a total debt of $20.29M, and net debt of - $48.51M. Total assets were $351.28M, with equity of $236.32M. Financials further reflected stability, with operating cash flow of $77.92M, free cash flow of $74.66M, and capital expenditures of - $3.26M.

Price Forecast & Outlook

Our AI price prediction model suggests that Voyager Therapeutics, Inc. stock has strong potential for upside but may face short-term weakness followed by gains in the medium and long term. 2-Week Outlook: Projected decline of -2.06%, with price expected at $3.80 by May 18, 2026, within a range of $3.52 to $4.10 3-Month Outlook: Projected rise of 35.31%, reaching $5.25 by July 31, 2026, with a range of $5.09 to $5.38. 1-Year Outlook: Projected gain of 208.51%, with price at $11.97 by May 04, 2027, within a range of $3.34 to $19.84.

Key Takeaways

Voyager Therapeutics, Inc. (NASDAQ:VYGR) shares are flat -6.62% year-to-date currently trading near 52-week highs band. Short-term momentum has been negative over the last quarter, despite recent volatility. Valuation shows Voyager Therapeutics, Inc. trading at a premium to the broader market with a P/E of -1.89. Analyst sentiment is bullish, with the majority of ratings in Buy territory and a mean price target of $19.80, suggesting 410.31% upside. Our AI forecast model points to short-term weakness (-2.06% over two weeks), a medium-term rise (35.31% over three months), and a longer-term gain (208.51% over one year), with expected trading ranges indicating moderate volatility.

Frequently Asked Questions

What is the current Voyager Therapeutics, Inc. (VYGR) stock price?

Voyager Therapeutics, Inc. (NASDAQ: VYGR) stock price is $3.88 in the last trading session. During the trading session, VYGR stock reached the peak price of $3.88 while $3.75 was the lowest point it dropped to. The percentage change in VYGR stock occurred in the recent session was 3.19% while the dollar amount for the price change in VYGR stock was $0.12.

VYGR's industry and sector of operation?

The NASDAQ listed VYGR is part of Biotechnology industry that operates in the broader Healthcare sector. Voyager Therapeutics, Inc. designs, manufactures, and markets smartphones, personal computers, tablets, wearables, and accessories worldwide.

Who are the executives of VYGR?

Mr. Todd Carter Ph.D.
Chief Science Officer
Dr. Mark A. Kay M.D., Ph.D.
Founder
Mr. Peter P. Pfreundschuh CPA
Chief Financial Officer
Dr. Phillip D. Zamore
Founder
Mr. Robert W. Hesslein
Senior Vice President & Gen. Counsel
Mr. G. Andre Turenne
Advisor
Dr. Alfred W. Sandrock Jr., M.D., Ph.D.
Pres, Chief Executive Officer & Director
Dr. Phillip D. Zamore Ph.D.
Founder & Member of Scientific Advisory Board
Dr. Krystof Bankiewicz M.D., Ph.D.
Founder
Ms. Robin Swartz
Chief Operating Officer
Ms. Michelle Quinn Smith
Chief HR Officer
Mr. Robert W. Hesslein Esq., J.D.
Senior Vice President & Gen. Counsel
Ms. Jacquelyn Fahey Sandell Esq., J.D.
Chief Legal Officer

How VYGR did perform over past 52-week?

VYGR's closing price is 46.41% higher than its 52-week low of $2.65 where as its distance from 52-week high of $5.55 is -30.09%.

How many employees does VYGR have?

Number of VYGR employees currently stands at 172.

Link for VYGR official website?

Official Website of VYGR is: https://www.voyagertherapeutics.com

How do I contact VYGR?

VYGR could be contacted at phone 857 259 5340 and can also be accessed through its website. VYGR operates from 75 Sidney Street, Lexington, MA 02139, United States.

How many shares of VYGR are traded daily?

VYGR stock volume for the day was 361.76K shares. The average number of VYGR shares traded daily for last 3 months was 655.34K.

What is the market cap of VYGR currently?

The market value of VYGR currently stands at $234.00M with its latest stock price at $3.88 and 60.31M of its shares outstanding.

Stocks Telegraph provides information and tools designed to assist investors and Wall Street players. A major goal is to offer financiers comprehensive information that will help them gain insight into investing.

Stocks Telegraph does not provide any advice or recommendations for buying or selling stocks, securities, or other financial products. Information contained on this website is for informational purposes only and should not be construed as professional financial, investment or other advice. Stocks Telegraph is not liable for any loss or damage that may occur as a result of reliance on this data.

Employees	172
Beta	1.38
Sales or Revenue	$250.01M
5Y Sales Change%	23.458%
Fiscal Year Ends	December
Sector	Healthcare
Industry	Biotechnology

VYGR Company Profile and Key Details

Voyager Therapeutics

Price Chart

Stock Price Today

Stock Snapshot

Relevant Articles

SEC Fillings

Current Report (8-k)

Annual Report (10-k)

Stock Price History Chart

Contact Details

About Company

Company Information

Stock Peers

Company Overview

Technical Performance

Valuation Metrics

Dividend & Fair Value

Earnings & Analyst Outlook

Shareholding & Insider Activity

Financial & Profitability Overview

Quarterly Financial Highlights

Price Forecast & Outlook

Key Takeaways

Frequently Asked Questions

Technical Performance

Financial & Profitability Overview

Quarterly Financial Highlights

Shareholding & Insider Activity

Earnings & Analyst Outlook

Company Overview

Dividend & Fair Value

Valuation Metrics

Key Takeaways

Price Forecast & Outlook